- Home
- HRTX vs SPXX Comparison
HRTX vs SPXX Comparison
Compare HRTX & SPXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRTX | SPXX |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.9M | 314.9M |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | HRTX | SPXX |
|---|---|---|
| Price | $1.28 | $18.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 51.3K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.55% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $155,097,000.00 | N/A |
| Revenue This Year | $8.98 | N/A |
| Revenue Next Year | $11.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.60 | N/A |
| 52 Week Low | $1.00 | $13.57 |
| 52 Week High | $2.68 | $16.05 |
Technical Indicators
Market Signals| Indicator | HRTX | SPXX |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 54.87 |
| Support Level | $1.19 | $17.55 |
| Resistance Level | $1.42 | $17.95 |
| Average True Range (ATR) | 0.07 | 0.20 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 30.65 | 88.14 |
Price Performance
Historical ComparisonAbout HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About SPXX Nuveen S&P 500 Dynamic Overwrite Fund
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on approximately 35%-75% of the notional value of the Fund's equity portfolio in an effort to enhance the Fund's risk-adjusted returns.